v3.26.1
Segment Reporting - Schedule of Segment Net Loss, Including Disaggregated Components of Operating Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Collaboration revenue $ 1,034 $ 566
Research and development:    
Personnel expenses 7,201 3,705
Manufacturing costs 4,973 2,129
Professional fees and other 1,630 1,492
Total research and development expenses 36,565 25,797
General and administrative:    
Personnel expenses 4,937 4,232
Professional fees 2,034 1,496
Other 1,113 1,054
Total general and administrative expenses 8,084 6,782
Total operating expenses 44,649 32,579
Loss from operations (43,615) (32,013)
Other income (expense):    
Interest income 3,054 4,743
Other expense, net (30) (0)
Total other income, net 3,024 4,743
Net loss (40,591) (27,270)
COPD Indication    
Research and development:    
Verekitug program 10,962 5,687
Asthma Indication    
Research and development:    
Verekitug program 10,710 10,021
CRSwNP Indication    
Research and development:    
Verekitug program $ 1,089 $ 2,763